NUT family member 2A antisense RNA 1 (NUTM2A-AS1)

NUT family member 2A antisense RNA 1 ("NUTM2A-AS1") is a long noncoding RNA mapped to human chromosome 19, classified as an antisense transcript of the NUTM2A gene[2]. It primarily acts as a competing endogenous RNA (ceRNA), sequestering specific microRNAs such as miR-376a, miR-126-5p, miR-let-7f, and others, thereby increasing the expression of oncogenic targets like TET1, HIF-1A, VEGFA, and MYH9[2][1]. NUTM2A-AS1 is distributed in the cytoplasm and sometimes the nucleus, influencing multiple cancer types by promoting cell proliferation, migration, invasion, immune evasion, and resistance to anticancer agents including matrine[2][4][5]. Its expression correlates with poor prognosis in cancers and is being investigated as a diagnostic, prognostic, and therapeutic target. Preclinical studies utilize approaches such as siRNA, antisense oligonucleotides, and CRISPR-based modulation to study and potentially inhibit its activity[2]. NUTM2A-AS1 may also modulate oxidative stress and inflammation in non-cancerous contexts[2][3].

Other names

NUTM2A antisense RNA 1FAM22A-AS1FAM22A antisense RNA 1NUTM2A-AS1

ceRNA mechanism: sequestration of microRNAs (miR-376a-3p, miR-126-5p, miR-613, miR-186-5p, miR-590-5p, miR-let-7f) to derepress specific oncogenes (e.g., TET1, HIF-1A, VEGFA, KLF7, YAP1, METTL3, PRMT5, MYH9); Regulation of immune checkpoint (PD-L1, B7-H3) expression